Revenue and Income - Revenues increased by €30.0 million, or 4%, from €751.4 million in 2022 to €781.4 million in 2023, driven by contributions from BMS and a new deal with Sandoz [202]. - Total revenues for Evotec Group increased to €781.4 million in 2023 from €751.4 million in 2022 [217]. - Revenues increased by €30 million, from €751.4 million in 2022 to €781.4 million in 2023, with €9.4 million related to private grants [224]. - Net income (loss) for 2023 was a loss of €83.9 million, compared to a loss of €175.7 million in 2022 [200]. - Net income improved by €91.7 million, or 52.2%, from a loss of €(175.7) million in 2022 to a loss of €(83.9) million in 2023 [224]. Costs and Expenses - Costs of revenue rose by €29.0 million, or 5.0%, from €577.4 million in 2022 to €606.4 million in 2023, primarily due to accelerated expenses for Biologics [203]. - Gross profit remained stable at €175.1 million in 2023, with a gross margin decrease to 22.4% from 23.2% in 2022 [200]. - R&D expenses decreased by €8.1 million, or 10.6%, from €76.6 million in 2022 to €68.5 million in 2023, reflecting lower expenses in Q2 [206]. - Other operating income decreased by €16.8 million, or 20.6%, from €81.6 million in 2022 to €64.8 million in 2023, mainly due to reduced income from Sanofi [209]. - Other operating expenses surged by €42.2 million, from €2.0 million in 2022 to €44.2 million in 2023, largely attributed to costs related to a cyber-attack [210]. - Adjusted EBITDA decreased by €35.3 million, or 35%, from €101.7 million in 2022 to €66.4 million in 2023 [226]. Financial Performance Metrics - Measurement result from investments improved by €163.0 million, from €(172.2) million in 2022 to €(9.1) million in 2023, primarily due to the fair value increase of Exscientia plc [213]. - Financial income increased by €0.9 million, or 11.1%, from €8.3 million in 2022 to €9.3 million in 2023 due to higher interest rates on short-term investments [211]. - Interest expense decreased by €1.4 million, or 10.7%, from €13.1 million in 2022 to €11.7 million in 2023 [212]. - Current tax expense decreased by €18.4 million, or 84.7%, to €3.3 million in 2023 from €21.7 million in 2022 [216]. Segment Performance - The EVT Innovate segment saw a revenue increase of €62.2 million, or 30%, from €204.7 million in 2022 to €266.9 million in 2023, driven by fee-for-service and FTE revenue [202]. - Segment operating income in the EVT Execute segment decreased by €75.5 million, or 232%, from €32.5 million in 2022 to €(43.0) million in 2023 [216]. - Segment Adjusted EBITDA in the EVT Execute segment decreased by €42.9 million, or 40%, from €108.3 million in 2022 to €65.4 million in 2023 [219]. - Segment operating loss in the EVT Innovate segment decreased by €7.2 million, or 62%, from €(11.7) million in 2022 to €(4.5) million in 2023 [219]. Customer Metrics - The number of customers increased from 819 in 2022 to 838 in 2023, while customers contributing over €1 million decreased from 118 to 102 [229][230]. - Annual repeat business rose to 93% in 2023 from 92% in 2022, indicating strong customer retention [231]. Cash Flow and Financing - As of December 31, 2023, cash and cash equivalents totaled €510.9 million, with undrawn credit lines amounting to €141.1 million [232]. - The company has drawn €93.3 million from a new €150 million financing agreement with the European Investment Bank as of December 31, 2023 [234]. - Total loan maturities for 2023 amounted to €436.1 million, up from €329.9 million in 2022 [236]. - For the fiscal year ended December 31, 2023, net cash flows from operating activities generated €36.4 million, despite a net loss of €84 million [242]. - Cash used in investing activities for the year ended December 31, 2023, amounted to €13.3 million, including €213.3 million for property, plant, and equipment [243]. - Net cash provided by financing activities for the year ended December 31, 2023, was €72.0 million, primarily from R&D and investment financing of €112.9 million [244]. - The repayment of lease obligations in financing activities for 2023 amounted to €22.4 million [244]. Future Investments - The company plans to invest approximately €170 million in capital expenditures in 2024, with €80 million allocated for two J.POD facilities [239]. - The company expects to commit roughly €90 million in new capital expenditures in 2024 for various facility expansions and lab equipment [239]. Currency and Risk Management - For the year ended December 31, 2023, 65% of the company's revenue was generated in U.S. dollars, and 11% in pound sterling [411]. - The company recorded a total cash outflow of €95,111 thousand for the year ended December 31, 2023, compared to a cash outflow of €265,131 thousand in 2022 [241]. - As of December 31, 2023, one customer accounted for 6% of the company's trade receivables, down from 22% in 2022, indicating improved credit risk management [416].

| --- | --- | --- | |---------------------------------------------|-------|-------------------------------| | | | | | | | | | | | | | Resetting for profitable growth | | | | | | SCIENTIFIC ES ONAL EXCELLENCE | | Evotec SE, Q1 2024 Analyst Call, 2024-05-22 | | | PAGE 2 #RESEARCHNEVERSTOPS This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company ...

Financial Data and Key Metrics Changes - Group revenues for 2023 were €781.4 million, a 4% increase compared to the previous year, despite significant operational impacts from a cyber incident [42][43] - Adjusted Group EBITDA for the year was €66.4 million, marking a 34% decline from last year, largely due to non-recoverable business and reduced capacity utilization in Q2 [44] - Gross margin declined to 22.6% from 23.2% due to the cyber incident and market challenges, with an adjusted gross margin of 27% excluding Just-Biologics [22][43] Business Line Data and Key Metrics Changes - Revenue from Just-Evotec Biologics reached €108.4 million, reflecting a remarkable increase of over 110% compared to the prior year, driven by strong partnerships [12] - The Innovate segment saw growth of more than 30%, primarily due to contract extensions with BMS in neurodegeneration and target protein degradation [45] - Execute segment revenues grew year-over-year, despite being adversely impacted by the cyber incident and a softening market towards the end of the year [46] Market Data and Key Metrics Changes - The share of biotech in the company's business decreased from approximately 40% to 34% due to fewer new funding events, indicating a challenging environment for biotech companies [39] - The company anticipates a market recovery towards 2025, with a cautious outlook for 2024 due to ongoing challenges in the biotech sector [28][39] Company Strategy and Development Direction - The company is focusing on profitability, efficiency, and high performance, with a strategic reset to align with market demands [9][30] - A new management structure has been introduced, including the appointment of a Chief People Officer to enhance organizational alignment and culture [11] - The company plans to optimize its organizational structure and operational model, with a target of generating annualized EBITDA improvements of over €40 million [79] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2023, including a cyber incident that resulted in €70 million in missed revenue, but expressed confidence in the company's ability to recover and grow [21][44] - The outlook for 2024 includes expectations of double-digit revenue growth, with a focus on Just-Evotec Biologics and differentiated offerings [36][80] - Management highlighted the importance of rebuilding momentum in the sales pipeline following the cyber incident and emphasized the need for careful monitoring of market conditions [66][96] Other Important Information - The company has made significant strides in sustainability, reducing Scope 1 and 2 emissions by 29% [23] - The new CEO, Dr. Christian Wojczewski, is expected to lead the company towards a prosperous future, leveraging his experience in transformational change [9][10] Q&A Session Summary Question: What are the expectations for 2024 and 2025? - Management indicated a qualitative guidance for 2024, expecting at least €100 million in EBITDA and €200 million plus in 2025, while acknowledging uncertainties [58][60] Question: What has changed in the market to prompt a more cautious outlook? - Management noted a decline in biotech funding and a challenging environment, leading to a cautious approach despite some early signs of recovery [64][66] Question: How is the order book looking across the broader business? - Management expressed confidence in the order book, indicating a double-digit growing demand and a strong pipeline, particularly in Just-Evotec Biologics [110]

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc ...

#researchneverstops | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | |---------------------------------------------------|-------|-------| | | | | | Evotec SE, 9M 2023 results call, 08 November 2023 | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | |---------------------------------|-------| | | | | | | | Emerging stronger | | | Pipeline building gaining speed | | Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Revenue Performance - Group revenues increased by 14% to €383.8 million in H1 2023, compared to €336.9 million in H1 2022, with like-for-like revenue growth also at 14%[4] - Total EVT Execute revenues rose by 2% to €356.6 million, while EVT Innovate revenues surged by 66% to €129.7 million in H1 2023[4] - Evotec reported a revenue of €383.835 million for the first half of 2023, an increase of 13.9% compared to €336.875 million in the same period of 2022[66] - Total revenues for the first half of 2023 amounted to €383,835k, representing a 14% increase compared to €336,875k in the same period of 2022[78][80] - Service fees and FTE-based research payments contributed €359,971k to total revenues, with a breakdown of €207,641k from Execute and €115,430k from Innovate[78] Financial Guidance - The company confirmed full-year 2023 revenue guidance of €750 – 790 million, with adjusted EBITDA guidance of €60 – 80 million[5] EBITDA and Profitability - Adjusted Group EBITDA for H1 2023 totaled €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-incident[4] - The company's Adjusted EBITDA for the first half of 2023 was €26.099 million, down from €33.636 million in the first half of 2022, reflecting a decrease of 22.4%[60] - Just – Evotec Biologics contributed an EBITDA of €8.5 million in H1 2023, with Q2 2023 showing a significant recovery to €20.0 million[26] - Net income for the first half of 2023 was a loss of €28.828 million, an improvement from a loss of €101.179 million in the same period of 2022[66] - The company’s total comprehensive income (loss) for the first half of 2023 was a loss of €18,478k, compared to a loss of €107,900k in the first half of 2022, reflecting a 82.9% improvement[69] Expenses and Costs - SG&A expenses increased by 31% to €88.2 million in H1 2023, driven by headcount growth to support business expansion[21] - Adjusted Group EBITDA for H1 2023 was €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-attack and higher management costs[25] - Cash flow from operating activities was €(5.2) million in H1 2023, a significant decline from €240.6 million in H1 2022, which was boosted by a $200 million upfront payment from BMS[32] Assets and Liabilities - Total assets increased by €44.0 million to €2,301.2 million as of 30 June 2023, with trade and other receivables rising by €30.7 million[37][38] - The company’s total financial assets as of June 30, 2023, were €1,008,060k, with cash and cash equivalents amounting to €459,752k[91] - The Group's total financial liabilities were €1,002,249k as of June 30, 2023, with loans and borrowings at €348,377k[92] - Total stockholders' equity decreased by 1% to €1,174.3 million as of 30 June 2023, with an equity ratio of 51.0%[46] Research and Development - Unpartnered R&D expenses are expected to be in the range of €60 – 70 million for FY 2023, consistent with €70 million in 2022[6] - Significant collaborations include a new agreement with Janssen for oncology therapies, with potential payments exceeding US$350 million over three years[12] - A milestone payment of €2 million was received from Bayer for the first patient dosed in a Phase I study of a kidney disease program[13] - R&D tax credits resulted in other operating income of €20.1 million in H1 2023, slightly up from €19.3 million in H1 2022[23] Cash Flow and Financing - Cash and cash equivalents increased to €459.752 million as of June 30, 2023, compared to €415.155 million at the end of 2022, representing a growth of 10.7%[64] - The company experienced a net cash inflow from financing activities of €10,480k in the first half of 2023, compared to a net outflow of €45,805k in the same period of 2022[68] - The company secured an unsecured loan facility of €150 million from the European Investment Bank to support R&D activities and the construction of a new production facility in Toulouse, France[74] Workforce and Growth - The workforce grew by 2.3% to 5,067 employees as of 30 June 2023, reflecting a net increase of 115 employees in the first half of the year[47] Market Performance - The company’s share price increased by 35% from the end of 2022 to June 30, 2023, significantly outperforming both the TecDAX and MDAX indices by more than 20%[62]

Exhibit 99.1 Notification of Major Holdings 2. Reason for notification (multiple reasons possible) 3. Details of person subject to the notification obligation | Natural person | | | | --- | --- | --- | | First name | Surname | Date of birth | Legal entity | Name including legal form (entity) | City of registered office | Country | | --- | --- | --- | | BlackRock, Inc. | New York, New York | United States of America (the) | Bundesanstalt für Finanzdienstleistungsaufsicht X Notification of Major Holdings or C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...